<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090362</url>
  </required_header>
  <id_info>
    <org_study_id>TRI08888</org_study_id>
    <nct_id>NCT01090362</nct_id>
  </id_info>
  <brief_title>Global Anticoagulant Registry in the Field</brief_title>
  <acronym>GARFIELD-AF</acronym>
  <official_title>Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thrombosis Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Advanced Drug and Device Services SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apothecaries Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thrombosis Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is
      a pioneering real-world prospective registry - one of the largest in the field of
      non-valvular atrial fibrillation (AF). With an eventual enrolment target of 55,000 patients,
      GARFIELD-AF aims to enhance understanding of stroke prevention in patients with non-valvular
      AF worldwide and help in defining future treatment strategies that may eventually influence
      patient outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using data from more than 1000 randomly selected centres across 35 countries, representing
      all possible care settings, the registry will help to characterize real-life anticoagulant
      treatment patterns and outcomes, including rates of stroke and bleeding complications, as
      well as provide data on other important issues, such as physicians' compliance with
      guidelines and patients' adherence to therapy. This is particularly timely as standard
      practice moves away from vitamin K antagonist (VKA)-dominated therapy and towards a new era
      of novel oral anticoagulants (OACs), i.e. direct Factor Xa inhibitors and direct thrombin
      inhibitors.

      To ensure a dataset that truly reflects current practice, the investigators are requested to
      prospectively enrol all newly diagnosed patients with non-valvular AF who have at least one
      additional investigator-determined risk factor for stroke. Patients are consecutively
      recruited into one of five cohorts and followed up for at least 2 years.

      With 3 cohorts complete and 36,000 enrolled GARFIELD-AF continues to recruit patients and, in
      conjunction with other registries and non-interventional studies, will be the source of
      further informative and useful data in the coming years. The findings will serve to increase
      our understanding of the management of patients with AF and improve our practice for their
      benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with oral anticoagulant treatment</measure>
    <time_frame>4, 8, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strokes (Haemorrhagic and thrombotic)</measure>
    <time_frame>4 monthly for 24 mths then annually until 2018</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">55000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Cohort completed with 11,351 patients enrolled from 30 countries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Cohort 3 completed with 11,139 patients enrolled globally from 32 countries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>Cohort 4 ongoing (commenced Aug 2014) with 2600 patients recruited to date and a target of 11,000 patients enrolled from 35 countries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <description>Final cohort to commence August 2015 with a target of 11,000 patients enrolled. Last patient enrolled to complete 2 years of follow-up.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients newly diagnosed with permanent atrial fibrillation (AF) who are
        with at least one additional risk of stroke from 18 countries globally.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Prospective Cohort

          -  Written informed consent

          -  Age 18 years and older

          -  New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks)
             with at least one additional risk factor for stroke and regardless of therapy.

        Retrospective validation cohort

          -  Written informed consent

          -  Age 18 years and older

          -  Diagnosis of non-valvular AF (diagnosed 6-24 months prior to enrolment) with at least
             one additional risk factor for stroke and regardless of therapy.

        Exclusion criteria:

          -  No further follow-up envisaged or possible within enrolling hospital or with
             associated family practitioner.

          -  Patients with transient AF secondary to a reversible cause.

          -  Patients recruited in controlled clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay K Kakkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Thrombosis Research Institute, London, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Kayani</last_name>
    <phone>00442073518390</phone>
    <email>gkayani@tri-london.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oscar Howie</last_name>
    <phone>00442073518316</phone>
    <email>ohowie@tri-london.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prof. Samuel Goldhaber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Goldhaber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Hector Luciardi, National Co-ordinating Investigator, National University of Tucuman</name>
      <address>
        <city>Tucum√°n</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Luciardi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harry Gibbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marianne Brodmann: National Co-ordinating Investigator, Medizinische Universit√§t Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marianne Brodmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Frank Cools, National Co-ordinating Investigator, AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Cools</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Antonio Barretto, National Coordinating Investigator, Hospital Santa Marcelina,</name>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Barretto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Stuart Connolly and Dr John Eikelboom, National Coodinating Investigators, Mc Master University</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Eikelboom, Hamilton General Hospital</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Ramon Corbalan, National Coordinating Investigator, Pontifica Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Corbalan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Dayi Hu, National Coordinating Investigator, Peking University People Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dayi Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Petr Jansky, National Coordinating Investigator, Cardiovaskular Center, Motol Univesity Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Jansky</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Joern Dalsgaard Nielsen, National Coordinating Investigator, Bispebjerg &amp; Frederiksberg Hospitals</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joern D Nielsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Hany Ragy, National Coordinating Investigator, Hayat Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hany Ragy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Pekka Raatikainen, National Coordinating Investigator, Univesrsity of Tampere</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pekka Raatikainen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yues LeHeuzey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Harald Darius, National oordinating Investigator, Vivantes Klinikum Neuk√∂lln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Darius</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Matyas Keltai, National Coordinating Investigator, Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matyas Keltai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Sanjay Kakkar, National Coordinating Investigator, Jai Medica Pvt Ltd</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Kakkar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Profs Giancarlo Agnelli and Giuseppe Ambrosio, National Coordinating Investigators, University of Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiseppe Ambrosio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Professor Yukihiro Koretsune, National Coordinating Investigator, Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukihiro Koretsune</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Seil Oh, National Coordinating Investigator, National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seil Oh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Carlos Jerjes Sanchez Diaz, National Coordinating Investigator,Tecnologico de Monterrey</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos JS Diaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Professor Hugo ten Cate, National Coordinating Investigator, Cardiovascular Research Institute Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo ten Cate</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Professor Dan Atar, National Coordinating Investigator, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Atar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Janina Stƒôpi≈Ñska, National Coordinating Investigator, Institute of Cardiology, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janina Stƒôpi≈Ñska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Professor Elizaveta Panchenko, National Coordinating Investigator, Cardiology Research and Production Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizaveta Panchenko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Toon Wei Lim, National Coordinating Investigator, National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toon Wei Lim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Jacobson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Xavier Vinolas, National Coordinating Investigator, Hospital Santa Creu y San Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Vinolas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Marten Rosenqvist, National Coordinating Investigator, Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr Jan Steffel, National Coordinating Investigator, University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof. Pantep Angchaisuksiri, National Coordinating Investigator, Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drs. Ali Oto and Murat Ersanli, National Coordinating Investigators, Hacettepe University &amp; Istambul Cardiology Institute respectively</name>
      <address>
        <city>Istambul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Oto - Ankara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Alexandr Parkhomenko, National Coordinating Investigator, Strazhesko Institute of Cardiology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandr Parkhomenko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Wael Al Mahmeed, National Coordinating Investigator, SKMC Cardiac Siences</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael Al Mahmeed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. David Fitzmaurice, National Coordinating Investigator, University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Fitzmaurice</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-london.ac.uk/garfield</url>
    <description>Sponsor's website</description>
  </link>
  <reference>
    <citation>Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012 Jan;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011. Epub 2011 Nov 20.</citation>
    <PMID>22172431</PMID>
  </reference>
  <reference>
    <citation>Apenteng PN, Murray ET, Holder R, Hobbs FD, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord. 2013 Apr 23;13:31. doi: 10.1186/1471-2261-13-31.</citation>
    <PMID>23617744</PMID>
  </reference>
  <reference>
    <citation>Aalbers J. GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry. Cardiovasc J Afr. 2012 Oct;23(9):528.</citation>
    <PMID>23108524</PMID>
  </reference>
  <results_reference>
    <citation>Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.</citation>
    <PMID>23704912</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Stroke prevention</keyword>
  <keyword>Health Economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

